Spotlight on Gynecology/Obstetrics

Credits: 0.75 CME
On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer
Joyce O'Shaughnessy, MD
University of Nebraska Medical Center

On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

Gynecology/Obstetrics Presentations

1.00 CME / MOC
Global Education Group
The HER Family: A Pan Tumor Approach

The HER Family: A Pan Tumor Approach

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

0.75 CME
Integrity Continuing Education, Inc.
Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer

Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: April 8, 2021
Expires: April 8, 2022
45 minutes to complete

Accredited By

Provided by Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).

Learning Objectives

  • Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
  • Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
  • Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
  • Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life

Activity Description

Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.

In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.

Faculty

Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island


Shannon N. Westin, MD, MPH (Faculty Chair)
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro (Institutional funds)

Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: April 8, 2021
Expires: April 8, 2022
45 minutes to complete

Accredited By

Provided by Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).

Learning Objectives

  • Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
  • Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
  • Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
  • Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life

Activity Description

Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.

In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.

Faculty

Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island


Shannon N. Westin, MD, MPH (Faculty Chair)
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro (Institutional funds)

Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

0.75 CME
University of Nebraska Medical Center
On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer

On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME / MOC
Vindico
Managing Cardiovascular Disease Risk in Women

Managing Cardiovascular Disease Risk in Women

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™ /
ABIM MOC
Released: September 30, 2020
Expires: September 29, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe traditional and female-predominant factors that contribute to CVD risk in women.
  • Outline available screening tools and guidelines to identify women with elevated CVD risk.
  • Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
  • Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
  • Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.

Activity Description

Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.

Agenda

Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC

Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Faculty

Activity Co-Chairs:

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ

Disclosure: No relevant financial relationships to disclose.


Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) MOC program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™ /
ABIM MOC
Released: September 30, 2020
Expires: September 29, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe traditional and female-predominant factors that contribute to CVD risk in women.
  • Outline available screening tools and guidelines to identify women with elevated CVD risk.
  • Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
  • Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
  • Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.

Activity Description

Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.

Agenda

Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC

Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Faculty

Activity Co-Chairs:

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ

Disclosure: No relevant financial relationships to disclose.


Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) MOC program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com